Oral News and Research

RSS

CBT improves blood sugar control and brings faster relief of depression in patients with type 2 diabetes

Although maintaining good blood sugar control is crucial for avoiding complications of diabetes, it has been estimated that only about half of patients are successful in meeting target blood glucose levels.

25 Feb 2014

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

An updated guideline from the American Academy of Neurology recommends that people with nonvalvular atrial fibrillation, or irregular heartbeat, take oral anticoagulants, a type of blood thinner pill, to prevent stroke.

25 Feb 2014

Scientists identify lung-damaging molecule in cystic fibrosis patients during symptom flare-ups

A molecule previously linked to lung injuries in factory workers producing microwave popcorn might play an important role in microbial infections of the lung suffered by people with cystic fibrosis (CF), according to a recent study led by San Diego State postdoctoral researcher Katrine Whiteson.

25 Feb 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

Researchers discover 'microbial Pompeii' preserved on teeth of skeletons around 1,000 years old

An international team of researchers have discovered a 'microbial Pompeii' preserved on the teeth of skeletons around 1,000 years old. The key to the discovery is the dental calculus (plaque) which preserves bacteria and microscopic particles of food on the surfaces of teeth, effectively creating a mineral tomb for microbiomes.

24 Feb 2014

Computerized safety checklist shows threefold drop in rates of serious type of hospital-acquired infection

A computerized safety checklist that automatically pulls information from patients' electronic medical records was associated with a threefold drop in rates of one serious type of hospital-acquired infection, according to a study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford.

24 Feb 2014

Study: Tooth decay may have detrimental effect on child's quality of life and success in life

Dental caries, commonly known as tooth decay, is the single most common chronic childhood disease. In fact, it is an infectious disease. Mothers with cavities can transmit caries-producing oral bacteria to their babies when they clean pacifiers by sticking them in their own mouths or by sharing spoons.

23 Feb 2014

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

MATH biomarker with HPV status may provide improved outcomes in HNSCC patients

Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

HPV-positive oropharyngeal cancer patients show longer survival pattern than those related to smoking

People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests.

21 Feb 2014

Reduction of RT to IB lymph nodes may result in better salivary function in head, neck cancer patients

For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

Most people have heard of severe allergies, or anaphylaxis, to food, insect stings, drugs and other common substances, but sometimes no cause at all can be found for a person’s reaction – a condition called Idiopathic anaphylaxis.

21 Feb 2014

MDA supports Minnesota Department of Human Services on dental access and reimbursement

The Minnesota Dental Association (MDA) supports the findings of a long-awaited report from the Minnesota Department of Human Services (DHS) on dental access and reimbursement.

21 Feb 2014

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

21 Feb 2014

Oral News and Research

CBT improves blood sugar control and brings faster relief of depression in patients with type 2 diabetes

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

Scientists identify lung-damaging molecule in cystic fibrosis patients during symptom flare-ups

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Researchers discover 'microbial Pompeii' preserved on teeth of skeletons around 1,000 years old

Computerized safety checklist shows threefold drop in rates of serious type of hospital-acquired infection

Study: Tooth decay may have detrimental effect on child's quality of life and success in life

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

MATH biomarker with HPV status may provide improved outcomes in HNSCC patients

HPV-positive oropharyngeal cancer patients show longer survival pattern than those related to smoking

Reduction of RT to IB lymph nodes may result in better salivary function in head, neck cancer patients

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

MDA supports Minnesota Department of Human Services on dental access and reimbursement

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Medicines that mimic body's natural systems can prevent debilitating side effects

State highlights: Kan. eyes health law opt-out; Calif. voters could set malpractice cap

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News